Valley National Advisers’s AIM ImmunoTech AIM Stock Holding History

Valley National Advisers’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-5	Closed	-$1K	–	907
2020 Q1	$1K	Buy	+5	New	+$784	﹤0.01%	747

Other funds holding AIM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SWM

SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

SAMH

Shanda Asset Management Holdings Tortola,, British Virgin Islands $1.85B AUM 36.09% 1-Year Est. Return

Valley National Advisers's AIM Position: Q2 2020 in Review

Valley National Advisers sold out of AIM ImmunoTech (AIM) in Q2 2020, closing a stake of 5 shares — an estimated $1K sold.

Valley National Advisers first reported a position in AIM in Q1 2020 and held it in 1 quarter. The position peaked at $1K in Q1 2020. 22 funds tracked by Wall St. Rank hold AIM as of Q2 2020.

Valley National Advisers reported no remaining AIM ImmunoTech position as of Q2 2020 after selling out during the quarter.
Valley National Advisers sold 5 AIM ImmunoTech shares in Q2 2020, an estimated $1K.
Valley National Advisers first reported a position in AIM ImmunoTech in Q1 2020 and held it in 1 quarter.
Valley National Advisers's AIM ImmunoTech position peaked at $1K in Q1 2020.
22 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2020.

Based on Valley National Advisers's 13F filing for Q2 2020, filed 10 Aug 2020.